Suppr超能文献

健康成年志愿者中身体成分、剂型和喂养对扑热息痛和布洛芬的群体药代动力学建模的影响。

Population Pharmacokinetic Modelling of Acetaminophen and Ibuprofen: the Influence of Body Composition, Formulation and Feeding in Healthy Adult Volunteers.

机构信息

Department of Pharmacology and Clinical Pharmacology, University of Auckland, Park Road, Auckland, 1023, New Zealand.

AFT Pharmaceuticals Limited, Auckland, New Zealand.

出版信息

Eur J Drug Metab Pharmacokinet. 2022 Jul;47(4):497-507. doi: 10.1007/s13318-022-00766-9. Epub 2022 Apr 2.

Abstract

BACKGROUND AND OBJECTIVE

Combined acetaminophen and ibuprofen are common antipyretic and analgesic drugs. Formulation and feeding affect drug absorption. Drug clearance has a nonlinear relationship with total body weight. The covariate effect of fat mass on acetaminophen and ibuprofen pharmacokinetics remains unexplored. This study sought to quantify acetaminophen and ibuprofen pharmacokinetics with intravenous, tablet, sachet and oral suspension formulations in fed and fasted states.

METHODS

Pooled time-concentration data for acetaminophen and ibuprofen were available from fasting and fed healthy adults. Data from intravenous, tablet, sachet and suspension formulations were analysed using nonlinear mixed-effects models. Body composition was considered as a covariate on clearances and volumes of distribution (V). Size metrics investigated were total body weight, fat and fat-free mass. Theory-based allometry was used to scale pharmacokinetic parameters to a 70 kg individual. A factor on absorption half-life and lag time quantified delays due to feeding for oral formulations. Pharmacokinetic-pharmacodynamic simulations were used to explore the time courses of pain response for acetaminophen and ibuprofen for each formulation.

RESULTS

Pooled data included 116 individuals (18-49 years, 49-116 kg) with 6095 acetaminophen and 6046 ibuprofen concentrations available for analysis. A two-compartment pharmacokinetic model with first-order elimination described disposition for both drugs. Normal fat mass was the best covariate to describe acetaminophen clearance (CL), with a factor for fat contribution (FFATCL) of 0.816. Acetaminophen volume of distribution was described using total body weight. Normal fat mass was the best covariate to describe ibuprofen clearance (FFATCL = 0.863) and volume of distribution: (FFATV = 0.718). Clearance and central volume of distribution were 24.0 L/h/70 kg and 43.5 L/h/70 kg for acetaminophen. Ibuprofen clearance and central volume of distribution were 3.79 L/h/70 kg and 10.5 L/h/70 kg. Bioavailability and absorption half-life were 86% and 12 min for acetaminophen and 94% and 27 min for ibuprofen. Absorption lag times were 5.3 min and 6.7 min for acetaminophen and ibuprofen, respectively. Feeding increased both absorption half-life and absorption lag time when compared to the tablet formulation under fasting conditions. Feeding had the most pronounced effect on the lag time associated with tablet formulation for both drugs. Time to a pain score reduction of 2 points (visual analogue score, 0-10) differed by only 5-10 min across all formulations for acetaminophen and ibuprofen.

CONCLUSION

Fat mass was an important covariate to describe acetaminophen and ibuprofen pharmacokinetics. The absorption half-lives of acetaminophen and ibuprofen were increased in fed states. The delay in absorption, quantified by a lag time, was protracted for both drugs.

摘要

背景和目的

对乙酰氨基酚和布洛芬联合使用是常见的解热镇痛药物。制剂和喂养方式会影响药物吸收。药物清除与总体重呈非线性关系。脂肪质量对乙酰氨基酚和布洛芬药代动力学的协变量影响仍未得到探索。本研究旨在定量研究空腹和进食状态下静脉、片剂、小袋和口服混悬剂制剂中对乙酰氨基酚和布洛芬的药代动力学。

方法

对乙酰氨基酚和布洛芬的空腹和进食健康成人的时间-浓度数据进行了汇总。使用非线性混合效应模型分析静脉、片剂、小袋和混悬剂制剂的数据。身体成分被视为清除率和分布容积(V)的协变量。研究的大小指标包括总体重、脂肪和去脂体重。基于理论的异速生长用于将药代动力学参数转化为 70 公斤个体。吸收半衰期和滞后时间的一个因子量化了口服制剂因喂养引起的延迟。药代动力学-药效学模拟用于探索每种制剂的对乙酰氨基酚和布洛芬的疼痛反应时间过程。

结果

汇总数据包括 116 名(18-49 岁,49-116 公斤)个体,可分析 6095 个对乙酰氨基酚和 6046 个布洛芬浓度。具有一级消除的两室药代动力学模型描述了两种药物的处置情况。正常脂肪量是描述对乙酰氨基酚清除率(CL)的最佳协变量,脂肪贡献因子(FFATCL)为 0.816。对乙酰氨基酚的分布容积使用总体重来描述。正常脂肪量是描述布洛芬清除率(FFATCL=0.863)和分布容积(FFATV=0.718)的最佳协变量。对乙酰氨基酚的清除率和中央分布容积分别为 24.0 L/h/70 kg 和 43.5 L/h/70 kg。布洛芬的清除率和中央分布容积分别为 3.79 L/h/70 kg 和 10.5 L/h/70 kg。生物利用度和吸收半衰期分别为 86%和 12 分钟的对乙酰氨基酚和 94%和 27 分钟的布洛芬。吸收滞后时间分别为 5.3 分钟和 6.7 分钟的对乙酰氨基酚和布洛芬。与空腹状态下的片剂制剂相比,进食会增加两种药物的吸收半衰期和吸收滞后时间。进食对两种药物的片剂制剂吸收滞后时间的影响最为显著。达到疼痛评分降低 2 分(视觉模拟评分,0-10)的时间仅相差 5-10 分钟,适用于所有对乙酰氨基酚和布洛芬制剂。

结论

脂肪量是描述对乙酰氨基酚和布洛芬药代动力学的重要协变量。对乙酰氨基酚和布洛芬的吸收半衰期在进食状态下增加。吸收延迟,用滞后时间来定量,对两种药物来说都是延长的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b793/9232434/3b434fa44ae6/13318_2022_766_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验